Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Schermuly, Ralph T ^a   Pullamsetti, Soni S ^a   Breitenbach, Susanne C ^a   Weissmann, Norbert ^a   Ghofrani, Hossein A ^a   Grimminger, Friedrich ^a   Nilius, Sigrid M ^b   Schrör, Karsten ^b   Meger Kirchrath, Jutta ^b   Seeger, Werner ^a   Rose, Frank ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CYCLIC AMP; FORSKOLIN; ILOPROST; PROSTACYCLIN RECEPTOR; VASODILATOR AGENT;

ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; CULTURE TECHNIQUE; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG TOLERANCE; FEMALE; HYPERTENSION, PULMONARY; INFUSION; INHALATIONAL DRUG ADMINISTRATION; LUNG; MALE; METABOLISM; RABBIT; SMOOTH MUSCLE FIBER;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ADMINISTRATION, INHALATION; ANIMALS; CELL CULTURE TECHNIQUES; COLFORSIN; CYCLIC AMP; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; FEMALE; HYPERTENSION, PULMONARY; ILOPROST; INFUSIONS, PARENTERAL; LUNG; MALE; MYOCYTES, SMOOTH MUSCLE; RABBITS; RECEPTORS, EPOPROSTENOL; VASODILATOR AGENTS;

EID: 46849105541     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-4     Document Type: Article

References (62)

1. Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol 1995, 75:3A-10A. 10.1016/S0002-9149(99)80377-4, 7840052.
2. Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M. Cloning and expression of a cDNA for the human prostanoid IP receptor. J Biol Chem 1994, 269:12173-12178.
3. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994, 46:205-229.
4. Namba T, Oida H, Sugimoto Y, Kakizuka A, Negishi M, Ichikawa A, Narumiya S. cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla. J Biol Chem 1994, 269:9986-9992.
5. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661-690. 10.1146/annurev.pharmtox.41.1.661, 11264472.
6. Negishi M, Sugimoto Y, Ichikawa A. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1995, 1259:109-119.
7. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001, 108:25-30. 209349, 11435452, 10.1172/JCI200113455.
8. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999, 79:1193-1226.
9. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004, 103:147-166. 10.1016/j.pharmthera.2004.06.003, 15369681.
10. Wise H, Jones RL. Focus on prostacyclin and its novel mimetics. Trends Pharmacol Sci 1996, 17:17-21. 10.1016/0165-6147(96)81565-3, 8789354.
11. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta 2000, 1483:285-293.
12. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 1997, 122:217-224. 10.1038/sj.bjp.0701367, 9313928.
13. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327:70-75.
14. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932.
15. Iwai N, Katsuya T, Ishikawa K, Mannami T, Ogata J, Higaki J, Ogihara T, Tanabe T, Baba S. Human prostacyclin synthase gene and hypertension the Suita Study. Circulation 1999, 100:2231-2236.
16. Geraci MW, Gao B, Shepherd DC, Moore MD, Westcott JY, Fagan KA, Alger LA, Tuder RM, Voelkel NF. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 1999, 103:1509-1515. 408370, 10359560.
17. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group [see comments]. N Engl J Med 1996, 334:296-302. 10.1056/NEJM199602013340504, 8532025.
18. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB, Diehl JH, Crow J, Long W. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990, 112:485-491.
19. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996, 124:820-824.
20. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329. 10.1056/NEJMoa020204, 12151469.
21. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, Wasserman K, Oudiz R, Shapiro S, Robbins IM, Channick R, Badesch D, Rayburn BK, Flinchbaugh R, Sigman J, Arneson C, Jeffs R. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003, 41:2119-2125. 10.1016/S0735-1097(03)00463-7, 12821234.
22. Galie N, Humbert M, Vachiery JL, Vizza CD, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M, Chaouat A, Morand S, Besse B, Simonneau G. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002, 39:1496-1502. 10.1016/S0735-1097(02)01786-2, 11985913.
23. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension [see comments]. N Engl J Med 1998, 338:273-277. 10.1056/NEJM199801293380501, 9445406.
24. Archer SL, Mike D, Crow J, Long W, Weir EK. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996, 109:750-755.
25. Zucker TP, Bonisch D, Hasse A, Grosser T, Weber AA, Schror K. Tolerance development to antimitogenic actions of prostacyclin but not of prostaglandin E1 in coronary artery smooth muscle cells. Eur J Pharmacol 1998, 345:213-220. 10.1016/S0014-2999(98)00022-3, 9600640.
26. Smyth EM, Nestor PV, FitzGerald GA. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor. J Biol Chem 1996, 271:33698-33704. 10.1074/jbc.271.25.14916, 8969241.
27. Nilius SM, Hasse A, Kuger P, Schror K, Meyer-Kirchrath J. Agonist-induced long-term desensitization of the human prostacyclin receptor. FEBS Lett 2000, 484:211-216. 10.1016/S0014-5793(00)02156-6, 11078881.
28. Le J, Shepherd M, Van HG, Houslay MD, Hall IP. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. J Biol Chem 2002, 277:35980-35989. 10.1074/jbc.M204832200, 12121997.
29. Mehats C, Tanguy G, Dallot E, Cabrol D, Ferre F, Leroy MJ. Is up-regulation of phosphodiesterase 4 activity by PGE2 involved in the desensitization of beta-mimetics in late pregnancy human myometrium?. J Clin Endocrinol Metab 2001, 86:5358-5365. 10.1210/jc.86.11.5358, 11701706.
30. Sobolewski A, Jourdan KB, Upton PD, Long L, Morrell NW. Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase. Am J Physiol Lung Cell Mol Physiol 2004, 287:L352-L359. 10.1152/ajplung.00270.2003, 15107293.
31. Seeger W, Walmrath D, Grimminger F, Rosseau S, Schutte H, Kramer HJ, Ermert L, Kiss L. Adult respiratory distress syndrome: model systems using isolated perfused rabbit lungs. Methods Enzymol 1994, 233:549-584.
32. Schermuly RT, Roehl A, Weissmann N, Ghofrani HA, Schudt C, Tenor H, Grimminger F, Seeger W, Walmrath D. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 2000, 292:512-520.
33. Schermuly RT, Krupnik E, Tenor H, Schudt C, Weissmann N, Rose F, Grimminger F, Seeger W, Walmrath D, Ghofrani HA. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med 2001, 164:1694-1700.
34. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D. Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J 2003, 22:342-347. 10.1183/09031936.03.00093802, 12952271.
35. Weissmann N, Voswinckel R, Hardebusch T, Rosseau S, Ghofrani HA, Schermuly R, Seeger W, Grimminger F. Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. Am J Physiol 1999, 276:L90-L95.
36. Shahbazian A, Heinemann A, Peskar BA, Holzer P. Differential peristaltic motor effects of prostanoid (DP, EP, IP, TP) and leukotriene receptor agonists in the guinea-pig isolated small intestine. Br J Pharmacol 2002, 137:1047-1054. 10.1038/sj.bjp.0704958, 12429577.
37. Rose F, Grimminger F, Appel J, Heller M, Pies V, Weissmann N, Fink L, Schmidt S, Krick S, Camenisch G, Gassmann M, Seeger W, Hanze J. Hypoxic pulmonary artery fibroblasts trigger proliferation of vascular smooth muscle cells: role of hypoxia-inducible transcription factors. FASEB J 2002, 16:1660-1661.
38. Darius H, Binz C, Veit K, Fisch A, Meyer J. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion. J Am Coll Cardiol 1995, 26:800-806. 10.1016/0735-1097(95)00264-5, 7543911.
39. Fisch A, Tobusch K, Veit K, Meyer J, Darius H. Prostacyclin receptor desensitization is a reversible phenomenon in human platelets. Circulation 1997, 96:756-760.
40. Smyth EM, Li WH, FitzGerald GA. Phosphorylation of the prostacyclin receptor during homologous desensitization. A critical role for protein kinase c. J Biol Chem 1998, 273:23258-23266. 10.1074/jbc.273.36.23258, 9722557.
41. Smyth EM, Austin SC, Reilly MP, FitzGerald GA. Internalization and sequestration of the human prostacyclin receptor. J Biol Chem 2000, 275:32037-32045. 10.1074/jbc.M003873200, 10889200.
42. Manganiello VC, Murata T, Taira M, Belfrage P, Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys 1995, 322:1-13. 10.1006/abbi.1995.1429, 7574662.
43. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998, 157:351-370.
44. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994, 266:L536-L543.
45. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A. PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal 2002, 14:277-284. 10.1016/S0898-6568(01)00250-9, 11812656.
46. Torphy TJ, Zhou HL, Foley JJ, Sarau HM, Manning CD, Barnette MS. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J Biol Chem 1995, 270:23598-23604. 10.1074/jbc.270.40.23598, 7559525.
47. Zhu B, Kelly J, Vemavarapu L, Thompson WJ, Strada SJ. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells. Biochem Pharmacol 2004, 68:479-491. 10.1016/j.bcp.2004.03.039, 15242814.
48. Seybold J, Newton R, Wright L, Finney PA, Suttorp N, Barnes PJ, Adcock IM, Giembycz MA. Induction of phosphodiesterases 3B, 4A4, 4D1, 4D2, and 4D3 in Jurkat T-cells and in human peripheral blood T-lymphocytes by 8-bromo-cAMP and Gs-coupled receptor agonists. Potential role in beta2-adrenoreceptor desensitization. J Biol Chem 1998, 273:20575-20588. 10.1074/jbc.273.32.20575, 9685415.
49. Murthy KS, Zhou H, Makhlouf GM. PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle. Am J Physiol Cell Physiol 2002, 282:C508-C517.
50. Borchert G, Bartel S, Beyerdorfer I, Kuttner I, Szekeres L, Krause EG. Long lasting anti-adrenergic effect of 7-oxo-prostacyclin in the heart: a cycloheximide sensitive increase of phosphodiesterase isoform I and IV activities. Mol Cell Biochem 1994, 132:57-67. 10.1007/BF00925675, 8078509.
51. Finney PA, Belvisi MG, Donnelly LE, Chuang TT, Mak JC, Scorer C, Barnes PJ, Adcock IM, Giembycz MA. Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo. J Clin Invest 2000, 106:125-135. 314356, 10880056.
52. Moravcova Z, Rudajev V, Stohr J, Novotny J, Cerny J, Parenti M, Milligan G, Svoboda P. Long-term agonist stimulation of IP prostanoid receptor depletes the cognate G(s)alpha protein in membrane domains but does not change the receptor level. Biochim Biophys Acta 2004, 1691:51-65. 10.1016/j.bbamcr.2003.12.004, 15053924.
53. Tanaka Y, Yamaki F, Koike K, Toro L. New insights into the intracellular mechanisms by which PGI2 analogues elicit vascular relaxation: cyclic AMP-independent, Gs-protein mediated-activation of MaxiK channel. Curr Med Chem Cardiovasc Hematol Agents 2004, 2:257-265. 10.2174/1568016043356273, 15320791.
54. Orie NN, Fry CH, Clapp LH. Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprost via a cyclic AMP-independent mechanism. Cardiovasc Res 2006, 69:107-115. 10.1016/j.cardiores.2005.08.004, 16183044.
55. Yamaki F, Kaga M, Horinouchi T, Tanaka H, Koike K, Shigenobu K, Toro L, Tanaka Y. MaxiK channel-mediated relaxation of guinea-pig aorta following stimulation of IP receptor with beraprost via cyclic AMP-dependent and -independent mechanisms. Naunyn Schmiedebergs Arch Pharmacol 2001, 364:538-550. 10.1007/s002100100485, 11770009.
56. Clapp LH, Turcato S, Hall S, Baloch M. Evidence that Ca2+-activated K+ channels play a major role in mediating the vascular effects of iloprost and cicaprost. Eur J Pharmacol 1998, 356:215-224. 10.1016/S0014-2999(98)00549-4, 9774252.
57. Turcato S, Clapp LH. Effects of the adenylyl cyclase inhibitor SQ22536 on iloprost-induced vasorelaxation and cyclic AMP elevation in isolated guinea-pig aorta. Br J Pharmacol 1999, 126:845-847. 10.1038/sj.bjp.0702383, 10193763.
58. Schubert R, Serebryakov VN, Engel H, Hopp HH. Iloprost activates KCa channels of vascular smooth muscle cells: role of cAMP-dependent protein kinase. Am J Physiol 1996, 271:C1203-C1211.
59. Schubert R, Serebryakov VN, Mewes H, Hopp HH. Iloprost dilates rat small arteries: role of K(ATP)- and K(Ca)-channel activation by cAMP-dependent protein kinase. Am J Physiol 1997, 272:H1147-H1156.
60. Fiessinger JN, Schafer M. Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study. Lancet 1990, 335:555-557. 10.1016/0140-6736(90)90346-7, 1689791.
61. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002, 26:194-201.
62. Smyth EM, Austin SC, FitzGerald GA. Activation-dependent internalization of the human prostacyclin receptor. Adv Exp Med Biol 2002, 507:295-301.